Autoimmune lung scarring registry for adults with recent diagnosis
Part of Bones, joints & muscles, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This registry collects health and breathing test information from adults with autoimmune-related lung scarring (interstitial lung disease) diagnosed recently. It helps researchers better understand who has this condition and how it changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You were diagnosed with interstitial lung disease within the past 5 years
- Your latest lung CT (HRCT) within the past 12 months shows scarring-type changes (like ground-glass areas or honeycombing)
- Your lung disease is linked to an autoimmune cause (for example, a connective-tissue disease, specific “IPAF” criteria, or certain ANCA blood test results), as judged by specialists
- You had breathing test spirometry within the past 6 months
- You must be willing and able to complete follow-up visits and any required study tests, and you must sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This is an observational (non-treatment) study that collects information about how interstitial lung disease (lung scarring) happens in people with certain autoimmune or immune-related conditions. It uses patient interviews or existing medical records to better understand the pattern and causes, which may help future care.
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
This study helps doctors identify early signs of lung scarring (fibrosis) in patients with autoimmune diseases like scleroderma, rheumatoid arthritis, and Sjögren's syndrome. By catching this early, researchers hope to better understand and treat these complications.
This trial is a study database that collects information from adults who have other illnesses that can increase the risk of developing interstitial lung disease (lung scarring). It may help researchers better understand who is at risk and how outcomes change over time.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
Hear when a new Interstitial Lung Disease Due to Systemic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.